Pipeline

Responding to the emerging market needs

As our company grows, our product range expands. Responding to the emerging market needs, we are currently working on a bevy of projects with many products at the final stages of development. As soon as the final product analysis take place, we will be able to proceed with registrations.

wdt_ID Molecule Form Strength Therapeutic Area Expected Launch
1 CEFPROZIL MONOHYDRATE Powder For Oral Suspension 250 mg/5 ml ANTIBIOTIC Q1 - 2019
2 CEFPROZIL MONOHYDRATE Film Coated Tablet 500 mg ANTIBIOTIC Q1 - 2019
3 DICLOFENAC SODIUM Gastroresistant Tablet 50 mg ORTHOPEDICS Q1 - 2019
4 EZETIMIBE Tablet 10 mg CARDIOLOGY Q1 - 2019
5 FLUTICASONE PROPIONATE + SALMETEROL XINAFOATE MDI, Metered-Dose Inhaler 125 mcg + 25 mcg/ 120 Doses, 250 mcg + 25 mcg/ 120 Doses ALLERGOLOGY & PULMONOLOGY Q4 - 2019
14 BUDESONIDE + FORMETEROL Mdi, Metered-Dose Inhaler 80 mcg + 4.5 mcg ALLERGOLOGY & PULMONOLOGY Q4 - 2019
15 BUDESONIDE + FORMETEROL Mdi, Metered-Dose Inhaler 160 mcg + 4.5 mcg ALLERGOLOGY & PULMONOLOGY Q4 - 2019
16 COLECALCIFEROL (VITAMIN D3) Hard Liquid Capsule 10000 IU, 25000 IU BLOOD DEFICIENCY Q4 - 2019